Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC).

Gayathri Anandappa,Naureen Starling,Ruwaida Begum,Annette Bryant,Shruti Sharma,Derrick Renner,Maria Aresu,Clare Peckitt,Himanshu Sethi,Andrew Feber, Vanessa Alice Potter,Marius Paraoan,Muti Abulafi,Nicol George,Graham Branagan,Sarah Duff,Nicholas West,Alexey Aleshin,Ian Chau,David Cunningham

Journal of Clinical Oncology（2021）

引用 22|浏览9

暂无评分

摘要

102Background: Numerous studies have shown the clinical utility of ctDNA, a non-invasive biomarker to detect MRD and stratify CRC patients who are more likely to relapse. We present an analysis of ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要